Právní předpis byl sestaven k datu 19.09.2014.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
XXXXXXX
Xxxxxxxxxxxx zahraničních xxxx,
xxxxxx xx mění x xxxxxxxx sdělení Xxxxxxxxxxxx zahraničních xxxx x. 58/2007 Xx. x. x. a x. 46/2008 Xx. x. x. x xxxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 97/2012 Xx. m. x. o Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx xxx 12. xxxxxxxxx 2012 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx xxxxx a xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve xxxxxx1).
X novým xxxxxx Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx v xxxxxxxx x souladu s xxxxxxx 34 xxxx. 3 Úmluvy xxx 1. xxxxx 2013 x tímto xxxx xxxxxxxxx v platnost x pro Xxxxxx xxxxxxxxx. Dnem xxxxxx xxxxxx xxxxx Přílohy X v platnost xxxxxxxx xxxxxx xxxxx Xxxxxxx I Xxxxxxxxxxx xxxxxx xxxxx dopingu xx sportu platné xx 1. ledna 2012 x vyhlášené xxx č. 97/2012 Sb. m. s.
Anglické xxxxx Přílohy I x xxxx xxxxxxx xx českého xxxxxx xx xxxxxxxxx xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx xxxxx dopingu xx sportu xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
PŘÍLOHA X
XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX ROK 2013
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. xxxxx 2013
Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx skupin S1, X2, S4.4, S4.5 x X6(x) x Xxxxxxxxxx xxxxx X1, X2 x X3.
| &xxxx;
XXXXX X XXXXXX XXXXXXXX XXXXX
(PŘI XXXXXXX X MIMO SOUTĚŽ)
|
XXXXXXXX XXXXX
X0. XXXXXXXXXXX XXXXX
Jakákoliv xxxxxxxxxxxxx xxxxx, která xxxx zahrnuta x xxxxxxxxxxxxx xxxxxxx Seznamu x xxxx aktuálně xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (xxxx. xxxxxx x preklinickém xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx ukončené xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
X1. XXXXXXXXXX LÁTKY
Xxxxxxxxxx xxxxx jsou xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); fluoxymesteron; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; metasteron (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); miboleron; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-dion); xxxxxxxxxx; norethandrolon; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; oxymesteron; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x další látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** AAS, xxxxx xxxx podány xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), androstendion (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx x jejich xxxxxxxxxx x isomery, xxx xx x xxxxxxxx xxxxx xx xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)
|
| &xxxx;
5α-xxxxxxxxx-3α,17β-xxxx
|
&xxxx; |
| &xxxx;
5α-xxxxxxxxx-3β,17α-xxxx
|
&xxxx;
xxx-xxxxxxxxxxxxxxxxxx
|
| &xxxx;
5α-xxxxxxxxx-3β,17β-xxxx
|
&xxxx;
xxxxxxxxxxxxxx
|
| &xxxx;
xxxxxxx-4-xx-3α,17α-xxxx
|
&xxxx;
3α-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-4-xx-3α,17β-xxxx
|
&xxxx;
3β-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
7α-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17α-xxxx
|
&xxxx;
7β-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17β-xxxX
|
&xxxx;
7-xxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
19-xxxxxxxxxxxxxx
|
| &xxxx;
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)
|
&xxxx;
19-xxxxxxxxxxxxxxxxx
|
2. Ostatní anabolické xxxxx, xxxxxxxxxx:
Klenbuterol, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SARM), tibolon, xxxxxxx, xxxxxxxxxx, xxx xx x omezením xxxxx xx ně.
|
Pro xxxxx xxxxxxx xxxx xxxxx: * "exogenní" xx xxxxxxxx x xxxxx, kterou tělo xxxx normálně xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx k xxxxx, xxxxxx xxxx tělo xxxxxxxxxx přirozeně.
|
X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX X XXXXXXXX LÁTKY
Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx faktory jsou xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (EPO), xxxxxxxxxxx (xXXX), stabilizátory xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx xxxxxx (LH) x mužů;
3. Xxxxxxxxxxxxxx;
4. Xxxxxxx xxxxxx (XX), fibroblastové xxxxxxx faktory (FGFs), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx podobný xxxxxxx xxxxxx-1 (XXX-1), xxxxxxxxxx růstové xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx z xxxxxxxx xxxxxxxx (XXXX) a xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx jiné xxxxxxx xxxxxxx xxxxxxxxxxx syntézu xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, regenerativní xxxxxxxx xxxx ovlivňující xxxx svalových xxxxxx;
x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
X3. XXXX2- XXXXXXXX
Všichni xxxx-2 agonisté xxxxxx xxxx případných xxxxxxxxx xxxxxxx (xxxx. x- x x-), jsou xxxxxxxx xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx xxxxx xxxx xxxxxx x inhalaci x xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx v xxxx v xxxxxxxxxxx xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x moči x koncentraci xxxxx xxx 40 xx/xx xxxxxx považována xx xxxxxxxxx terapeutické xxxxxxx, xxx xxxx považována xx pozitivní xxxxxxxxxxx xxxxx, pokud xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx abnormální xxxxxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx xxx xxxx uvedené xxxxxxx.
X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, anastrozol, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo),exemestan, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), zahrnující:
Xxxxxxxxx, xxxxxxxxx, toremifen, ale xx x xxxxxxxx xxxxx xx ně.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
4. Xxxxx modifikující xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx myostatinu, xxx xx s xxxxxxxx xxxxx xx ně.
5. Metabolické modulátory:
x) Xxxxxxxx;
x) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Peroxisome Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) xxxxxxxx/ (xxxx. GW 1516) x Agonisté xxxxxxxxxxxxxxx xxx xxxxxxxxxx XXX x xxxxxxxxxxx s XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx kinase (AMPK) xxxx xxxxxxxx/ (xxxx. XXXXX)
X5. XXXXXXXXX X XXXXXXX XXXXXXXXX XXXXX
Maskovací látky xxxx xxxxxxxx. Zahrnují:
Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. glycerol, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx a mannitolu), xxxxxxxxxx x xxxxx xxxxx s xxxxxxxxx xxxxxxxxxxxx účinky. Xxxxxxx xxxxxx felypressinu pro xxxxx xxxxxxxx xxxx xxxxxxxx.
Diuretika zahrnují:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, kyselina xxxxxxxxxx, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx x xxxxxxxxx xxxxxx dorzolamidu a xxxxxxxxxxxx, xxxxx nejsou xxxxxxxx).
Pro použití (Xxx Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. formoterol, salbutamol, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x pseudoefedrin) xx spojení x xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx látku xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
X1. XXXXXXXXXX X KRVÍ X XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx nebo xxxxxxxxxxxxx xxxxxxxxx, homologní xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x xxx xxxxxxxxx produktů xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.
2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx nebo dodávky xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx produkty (xxxx.xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, mikroenkapsulované hemoglobiny), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx xx x omezením pouze xx xx. Xxxxxxxxxxxx xxxxxxxx zakázána xxxx.
3. Jakákoliv xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx fyzikálními xxxx xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX X XXXXXXXXX MANIPULACE
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx při Xxxxxxxxx xxxxxxxx xx zakázané. Xx zahrnuje záměnu x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, ale xx s xxxxxxxx xxxxx xx xx.
2. Nitrožilní xxxxxx x/xxxx xxxxxxx více xxx 50 xx xx 6 hodin xxxx xxxxxxxx xxxxx xxxxxx xxxxxxxxx přijatých x průběhu nemocničních xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx metod.
X3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx xx xxxxxxx sportovního xxxxxx xx xxxxxxxx následující:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Použití xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx buněk;
|
XXXXX X XXXXXX ZAKÁZANÉ XXX XXXXXXX
|
Xxxxx kategorií S0 xx X5 x X1 xx X3 xxxxxxxxx výše xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx skupiny:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x x-) xxxx zakázaná, x xxxxxxxx xxxxxxxx xxxxxxxxx v xxxxxxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2013*.
Xxxxxxxxxxx xxxxxxxx:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, amfetaminil, amfetamin, xxxxxxxxxx, xxxxxxxxxx, benzfetamin, xxxxxxxxxxxxxxx, bromantan, dimethylamfetamin, xxxxxxxxxxxxxx, famprofazon, fendimetrazin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, fenproporex, xxxxxxxxx, 4-xxxxxxxxxxxxxx (karfedon), furfenorex, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, mefenorex, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, modafinil, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, které xxxx xxxxxxxx xxxxxxx x tomto xxxxxxxx, xx Xxxxxxxxxxx látkou.
(x) Xxxxxxxxxx stimulancia (xxxxxxxx):
Xxxxxxxxx**, xxxxx***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, metylefedrin****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), niketamid, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx látky s xxxxxxxx chemickou strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Následující xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2013 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx považovány xx Zakázané látky.
** Xxxxxxx podání xxxxxxxxxx (např. xxxxx, xxxx aplikace) nebo xxxx podání xxxxxxxx x lokálními anestetiky xxxx zakázáno.
*** Xxxxx xx zakázaný xxxxx xxx koncentraci xxxxx než 5 xxxxxxxxxx v 1 xx xxxx.
**** Xxxxxxx a xxxxxxxxxxxxx xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx v 1 xx xxxx.
***** Xxxxxxxxxxxxx je xxxxxxx, xxxxx jeho xxxxxxxxxxx x moči xx vyšší xxx 150 xxxxxxxxxx na xxxxxxxx
X7. NARKOTIKA
Xxxxxxxx xx následujíci:
Xxxxxxxxxxx, dextromoramid, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.
X8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, xxxxxx a xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (THC) x xxxxxxxxxxxxxx (xxxx. "Spice" /XXX018, XXX073/ x XX-210) xxxx zakázané.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx aplikací xxxx xxxxxxxx.
| &xxxx;
XXXXX ZAKÁZANÉ X URČITÝCH SPORTECH
|
P1. ALKOHOL
Xxxxxxx (xxxxxx) je xxxxxxxx xxxxx Xxx Xxxxxxx v následujících xxxxxxxx. Xxxxxxx xx xxxx provádět dechovou xxxxxxxx a/nebo rozborem xxxx. Prahová xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 x/x.
∙ Automobilový sport (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx x parašutismus(FAI)
∙ Xxxxxxxxxxx (XXXX)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. XXXX-XXXXXXXXX
Xxxxx není xxxxx určeno, xxxx-xxxxxxxxx xxxx xxxxxxxx pouze Xxx Soutěži v xxxxxxxxxxxxx xxxxxxxx.
∙ Xxxxxxxxxxxx xxxxx (FIA)
∙ Billiard (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxx (XXX)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - skoky xx xxxxxx a xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx,x xxxxxxxxx X-xxxxx x "big xxx"
∙ Xxxxxxx (XXXX, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxx (XXX)
Beta-blokátory xxxxxxxx následující látky:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, bisoprolol, bunolol, xxxxxxxxxx, esmolol, karteolol, xxxxxxxxxx, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, pindolol, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx x omezením xxxxx xx xx.
Xxxxxxxxx
Xxxxxx předpis x. 98/2013 Xx. x. x. xxxxx xxxxxxxxx xxxx 20.12.2013.
Xxxxxx xxxxxxx x. 98/2013 Xx. m. x. xxx zrušen právním xxxxxxxxx č. 47/2014 Sb. m. s. x xxxxxxxxx od 20.9.2014.
Xxxxx jednotlivých xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není aktualizováno, xxxxx se xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.